Atuzaginstat is under clinical development by Lighthouse Pharmaceuticals and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Atuzaginstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Atuzaginstat overview

COR-388 is under development for the treatment of Parkinson’s disease and periodontal disease. It is also used for the treatment of high-risk oral potentially malignant disorders (OPMDs), including oral/head and neck squamous cell cancer (O/HNSCC), high-risk oral pre-malignant dysplasia (PmD), proliferative verrucous leukoplakia (PVL), and carcinoma-in-situ (CIS). It is an orally-administered, brain-penetrating small molecule gingipain protease inhibitor.

It was also under development for mild to moderate Alzheimer's disease.

Lighthouse Pharmaceuticals overview

Lighthouse Pharmaceuticals (Lighthouse) is a biopharmaceutical company developing precision medicine candidates based on expertise in small molecule protease inhibition for the treatment of chronic degenerative and inflammatory disorders including dementia. Lighthouse is headquartered in Savannah, Georgia, the US.

For a complete picture of Atuzaginstat’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.